搜索优化
Rewards
English
搜索
Copilot
图片
视频
地图
资讯
购物
更多
航班
旅游
酒店
房地产
笔记本
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
时间不限
过去 1 小时
过去 24 小时
过去 7 天
过去 30 天
按相关度排序
按时间排序
3 小时
Buy Rating Affirmed for 2seventy bio Despite Trial Setback: Niche Market Strategy and ...
Daina Graybosch, an analyst from Leerink Partners, reiterated the Buy rating on 2seventy bio (TSVT – Research Report). The associated ...
2 天
on MSN
Bristol Myers, 2seventy bio halt enrollment in Abecma late-stage trial
(TSVT) stock lost as company with Bristol Myers Squibb (BMY) plan to discontinue enrollments in a Phase 3 trial for cancer ...
2 天
2seventy bio与百时美施贵宝停止多发性骨髓瘤疗法试验 预计节省8000万美元
据了解,2seventy bio和其合作伙伴百时美施贵宝宣布,将停止新诊断的多发性骨髓瘤患者使用的T细胞免疫疗法Abecma的III期临床试验。这项名为KarMMa-9的研究,旨在评估Abecma与来那度胺联合治疗,以及来那度胺单药治疗的效果。两家公司表示,这一决定是在对该研究的商业理由进行彻底审查后做出的。
FiercePharma
2 天
Citing enrollment challenges, Bristol Myers and 2seventy scrap Abecma trial in first-line ...
Bristol Myers Squibb’s struggling CAR-T therapy Abecma has hit a major setback. | Bristol Myers Squibb’s CAR-T therapy Abecma ...
生物谷
3 天
Clin Cancer Res:新研究表明CAR-T细胞治疗后继发性癌症的风险可能与 ...
据研究报告,在接受 CAR-T 细胞治疗之前,患者接受过中位数超过三种疗法的 SPM 风险明显高于之前接受过少于三种疗法的患者。同样,在随访时间低于中位数 21.7 个月的研究中,SPM 的发生率为 ...
2 天
Bristol Myers-2seventy Bio Halt Phase 3 Trial For Abecma In Newly Diagnosed Myeloma ...
KarMMa-9 trial for Abecma, saving $80 million and focusing on profitability by 2025. Despite the decision, the company ...
阿思達克財經網
2 天
2seventy bio(TSVT.US)与百时美施贵宝(BMY.US)停止多发性骨髓瘤疗法试验 ...
据了解,2seventy ...
Zacks.com on MSN
1 天
TSVT, BMY Discontinue Enrollment in Late-stage Abecma Study
TSVT announced that it will discontinue enrollment in its ongoing phase III KarMMa-9 study.The study is evaluating Abecma ...
Pharmabiz
23 小时
Bristol Myers Squibb, 2seventy bio to discontinue enrollment in phase 3 KarMMa-9 study of ...
Bristol Myers Squibb, 2seventy bio to discontinue enrollment in phase 3 KarMMa-9 study of Abecma in patients with newly diagnosed MM: Princeton, New Jersey Friday, September 27, 2 ...
Business Wire
2 天
2seventy bio Provides Update on KarMMa-9 Study and Previews Anticipated Strong Third ...
Inc. (Nasdaq: TSVT) today announced that the Company, in partnership with study sponsor Bristol Myers Squibb (BMS), will ...
1 天
Cobenfy Approval Brings 20% Upside To Bristol Myers Squibb Stock
This is a big approval for the company, given that Cobenfy doesn’t have the classic side effects seen in other antipsychotic ...
11 天
他山之石:日本细胞疗法的十年
通过建立《再生医学促进法》《再生医学安全法》等特殊法规监管途径,十多年来,日本不遗余力地鼓励细胞疗法的开发和商业化,批准了许多产品。它们大部分是由日本公司推出的,但也包括来自欧美MNC的CAR-T疗法。
当前正在显示可能无法访问的结果。
隐藏无法访问的结果
反馈